SYNGENE - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.1
| Stock Code | SYNGENE | Market Cap | 18,843 Cr. | Current Price | 468 ₹ | High / Low | 729 ₹ |
| Stock P/E | 52.1 | Book Value | 117 ₹ | Dividend Yield | 0.27 % | ROCE | 10.0 % |
| ROE | 7.74 % | Face Value | 10.0 ₹ | DMA 50 | 440 ₹ | DMA 200 | 552 ₹ |
| Chg in FII Hold | -1.05 % | Chg in DII Hold | 0.61 % | PAT Qtr | 154 Cr. | PAT Prev Qtr | 68.7 Cr. |
| RSI | 65.4 | MACD | 7.54 | Volume | 6,33,89,388 | Avg Vol 1Wk | 1,66,63,242 |
| Low price | 380 ₹ | High price | 729 ₹ | PEG Ratio | -6.19 | Debt to equity | 0.04 |
| 52w Index | 25.1 % | Qtr Profit Var | -11.8 % | EPS | 7.57 ₹ | Industry PE | 39.6 |
📈 Optimal Buy Price: 460–470 ₹ (near DMA50 support)
💰 Profit Exit Levels: 485–495 ₹ (short-term resistance zone)
🛑 Stop-Loss: Below 455 ₹ (protect downside risk)
🔄 Intraday Exit Guidance: If RSI (65.4) fails to sustain above 65 or price action struggles near 485 ₹ with weakening volume, consider booking profits. Exit intraday if MACD momentum fades or volume drops below average despite price holding above 465 ₹.
Positive
- Quarterly PAT improved significantly (154 Cr. vs 68.7 Cr.)
- EPS at 7.57 ₹ supports valuation strength
- DII holdings increased (+0.61%), showing domestic institutional support
- Price trading above DMA50 (440 ₹), confirming near-term strength
- Low debt-to-equity (0.04) ensures financial stability
Limitation
- Price below DMA200 (552 ₹), signaling medium-term weakness
- PEG ratio negative (-6.19), limiting valuation attractiveness
- FII holdings declined (-1.05%), showing reduced foreign confidence
- ROE (7.74%) and ROCE (10.0%) remain modest compared to peers
- Quarterly profit variation (-11.8%) raises caution
Company Negative News
- Sequential profit decline (-11.8%) despite recent recovery
- Weak return ratios compared to industry benchmarks
Company Positive News
- Strong quarterly PAT recovery
- Domestic institutional support (DII inflows)
- Technical support from DMA50 and strong trading volume
Industry
- Biopharma sector PE at 39.6, SynGene trades at premium (52.1), reflecting growth optimism
- Sector outlook stable with demand in contract research and biotech services
Conclusion
📌 SYNGENE is a moderately strong intraday candidate today. Buy near 460–470 ₹ with stop-loss at 455 ₹. Exit around 485–495 ₹ if momentum sustains. If RSI fails to hold above 65 or volume weakens, book profits early to protect gains.
Would you like me to also prepare a swing trade overlay (1–2 weeks) with peer benchmarking against Biocon, Divi’s Lab, and Laurus Labs to align intraday setups with sector positioning?